...
首页> 外文期刊>Chest: The Journal of Circulation, Respiration and Related Systems >Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines.
【24h】

Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines.

机译:表皮生长因子受体/ kirsten大鼠肉瘤2病毒癌症同源物突变检测以定义多肺腺癌中的克隆关系:与临床指南的比较。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: The incidence of multiple lung adenocarcinomas is rising, making it difficult to determine the stage and assign treatment in an increasing number of patients following surgery. Clinical guidelines have been developed to distinguish independent non-small cell lung cancers from metastases, that is, criteria developed by Martini and Melamed and the American College of Chest Physicians (ACCP). However, these guidelines can be difficult to apply and may give conflicting results. Here, we report on seven patients in whom epidermal growth factor receptor (EGFR) and Kirsten-rat sarcoma 2 viral oncogene homolog (KRAS) tumor mutation status was used to determine clonal relationships among multiple lung lesions. METHODS: We identified seven patients whose paired lung adenocarcinomas were found to harbor distinct EGFR or KRAS mutations. We assessed these patients' disease status using established clinical guidelines. We also explored the use of comprehensive histologic subtyping (CHS) of tumor sections to distinguish multiple primaries. RESULTS: According to the Martini-Melamed criteria, six of the seven patients had multiple primary lung tumors. By ACCP criteria, three patients had multiple primaries, and three patients had metastases. Classification of the seventh patient by ACCP criteria was indeterminate. Mutational testing suggested that all paired tumors were multiple primary adenocarcinomas, which was consistent with results from CHS. CONCLUSIONS: Assuming that independent tumor clones harbor distinct mutations, these seven cases highlight discrepancies between the existing clinical criteria used to distinguish independent tumor foci from metastases. EGFR/KRAS mutation testing of multiple lung adenocarcinomas can assist in differentiating multiple primary lung adenocarcinomas from metastatic lesions. Use of CHS in this setting should also be further explored.
机译:背景:多种肺腺癌的发病率升高,使得难以确定阶段并在手术后越来越多的患者分配治疗。已经开发出临床指南,以区分独立的非小细胞肺癌转移,即马蒂尼尼开发的标准,并培养和美国胸部医师学院(ACCP)。但是,这些准则可能难以申请,可能产生冲突的结果。在这里,我们报告了表皮生长因子受体(EGFR)和Kirsten-RAT SARCOMA 2病毒癌症同源物(KRAS)肿瘤突变状态的患者用于确定多种肺病变中的克隆关系。方法:鉴定了七名患者,发现肺腺癌的患者含有不同的EGFR或KRAS突变。我们使用已建立的临床指南评估了这些患者的疾病状态。我们还探索了使用综合组织学亚型(CHS)的肿瘤部分来区分多个原初级。结果:根据马提尼茂的标准,七名患者中有六种患者有多种原发性肺肿瘤。通过ACCP标准,三名患者有多个初选,三名患者有转移。 ACCP标准的第七患者的分类是不确定的。突变试验表明,所有配对的肿瘤都是多发性腺癌,这与CHS的结果一致。结论:假设独立肿瘤克隆港口不同的突变,这7例突出了现有的临床标准与区分转移的肿瘤灶区分的差异。多种肺腺癌的EGFR / KRAS突变试验可以帮助将多发性肺腺癌免于转移性病变。还应进一步探索在此环境中使用CHS。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号